ArticleDermatology and therapy2017
Topical Treatment of Rosacea with Ivermectin Inhibits Gene Expression of Cathelicidin Innate Immune Mediators, LL-37 and KLK5, in Reconstructed and Ex Vivo Skin Models.
Article in Dermatology and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Evaluation of the effect of an extract of Sphingomonas xenophaga present in a Thermal Spring Water in the management of sensitive skin associated with cutaneous vascular disorder.International journal of cosmetic science · 2025Trial
- Repurposing therapies in junctional epidermolysis bullosa: Oral ivermectin therapy associated with improved wound healing and reduced pruritus.JAAD case reports · 2026Article
- Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Rosacea scleritis and sclero-uveitis; under recognised and over treated.Journal of ophthalmic inflammation and infection · 2026Review
- UVB Upregulates Inflammatory Cytokines in Rosacea Cell Model by Promoting the Expression of TRPVs and TLR2.ImmunoTargets and therapy · 2026Article
- Virtual screening identifies specnuezhenide as a potential therapeutic agent for rosacea via KLK5/TLR4/NF-κB pathway inhibition and metabolic modulation.Frontiers in immunology · 2026Article
- Relationship of the Specific Inflammatory Cytokines KLK5, IL-8, and IL-22 withJournal of inflammation research · 2025Article
- Ivermectin decreases inflammation and imiquimod-induced psoriasis-like skin lesions in rat via targeting TLR4/p65 NF-κB.Iranian journal of basic medical sciences · 2025Article
- Potential Role of Tranexamic Acid in Rosacea Treatment: conquering Flushing Beyond Melasma.Clinical, cosmetic and investigational dermatology · 2024Review
- Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea.Frontiers in immunology · 2024Review
- The Development of Human Ex Vivo Models of Inflammatory Skin Conditions.International journal of molecular sciences · 2023Article
- Papulopustular Rosacea Treated With Ivermectin 1% Cream: Remission of the Demodex Mite Infestation Over Time and Evaluation of Clinical Relapses.Dermatology practical & conceptual · 2022Article
- Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study.International immunopharmacology · 2021Article
- Cutaneous and ocular rosacea: Common and specific physiopathogenic mechanisms and study models.Molecular vision · 2021Review
- A Novel Mechanism of Carvedilol Efficacy for Rosacea Treatment: Toll-Like Receptor 2 Inhibition in Macrophages.Frontiers in immunology · 2021Article
- Adipokines in the Skin and in Dermatological Diseases.International journal of molecular sciences · 2020Review
- [Granulomatous rosacea in a lung transplant recipient : A possible therapy option in a unique group of patients].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2020Article
- Utilizing Organoid and Air-Liquid Interface Models as a Screening Method in the Development of New Host Defense Peptides.Frontiers in cellular and infection microbiology · 2020Review
- New indications for topical ivermectin 1% cream: a case series study.Postepy dermatologii i alergologii · 2019Article
- Citron Essential Oils Alleviate the Mediators Related to Rosacea Pathophysiology in Epidermal Keratinocytes.Annals of dermatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNumerous intrinsic and extrinsic factors have been associated with the pathophysiology of rosacea, including dysregulation of innate immunity. A high level of cathelicidin antimicrobial peptides (e.g., LL-37) has been shown in the facial skin of patients with rosacea. Excessive production of both LL-37 and KLK5, the serine protease responsible for its cleavage, has been suggested to play a role in the pathophysiology of rosacea. Ivermectin 10 mg/g cream, indicated for the treatment of inflammatory lesions of rosacea, is reported to have dual anti-parasitic and anti-inflammatory properties. However, the exact mechanism of action of ivermectin cream in the treatment of rosacea is unknown.
methodsThis study aimed to evaluate the effect of ivermectin on the expression of KLK5 and the subsequent effect on the maturation process of cathelicidins. Experimental studies were performed either on normal human epidermal keratinocytes (NHEK), reconstructed human epidermis (RHE) or on human skin ex vivo stimulated with calcitriol (1α,25-dihydroxyvitamin D3), which is known to induce KLK5 and LL-37 expression.
resultsThe results show that ivermectin is able to inhibit KLK5 and CAMP gene expression and protein secretion in NHEK cells stimulated with calcitriol. Those results were confirmed in 3D models of the skin (RHE and skin ex vivo). The anti-inflammatory effects of ivermectin were associated with an inhibition of IL-8, IL-6 and MCP-1 (CCL2) secretion from NHEK cells.
conclusionsThese results suggest that ivermectin can prevent the inflammatory effects of rosacea triggered by abnormal LL-37 processing, through the inhibition of KLK5 gene expression in the epidermis.
fundingNestlé Skin Health R&D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.